Words of wisdom. Re: the efficacy and safety of degarelix: a 12-month, comparative, randomized, open- label, parallel-group phase III study in patients with prostate cancer.
Jocham
Dieter
D
Department of Urology, University of Lubeck Medical School, Lubeck, Germany. Prof.Jocham.MUL@t-online.de
Doehn
Christian
C